Level C· Early human research exploring benefitsCohort StudyEurope PMC

Toll-like receptors regulate B cell cytokine production in patients with diabetes

Jagannathan M., McDonnell M., McDonnell M., Liang Y., Hasturk H., Hetzel J.

Cohort Study on Type 1 Diabetes, Chronic Inflammation, published in Diabetologia (2010) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Cohort Study
Journal
Diabetologia (2010)
Reported sample size
—
Source database
Europe PMC
PMID
20383694
PMCID
PMC2895399
DOI
10.1007/s00125-010-1730-z
Citations
125

Abstract (original English)

Aims/hypothesis Understanding cellular and molecular events in diabetes mellitus will identify new approaches for therapy. Immune system cells are important modulators of chronic inflammation in diabetes mellitus, but the role of B cells is not adequately studied. The aim of this work was to define the function of B cells in diabetes mellitus patients through focus on B cell responses to pattern recognition receptors. Methods We measured expression and function of Toll-like receptors (TLRs) on peripheral blood B cells from diabetes mellitus patients by flow cytometry and multiplexed cytokine analysis. We similarly analysed B cells from non-diabetic donors and periodontal disease patients as comparative cohorts. Results B cells from diabetes mellitus patients secrete multiple pro-inflammatory cytokines, and IL-8 production is significantly elevated in B cells from diabetic patients compared with those from non-diabetic individuals. These data, plus modest elevation of TLR surface expression, suggest B cell IL-8 hyperproduction is a cytokine-specific outcome of altered TLR function in B cells from diabetes mellitus patients. Altered TLR function is further evidenced by demonstration of an unexpected, albeit modest 'anti-inflammatory' function for TLR4. Importantly, B cells from diabetes mellitus patients fail to secrete IL-10, an anti-inflammatory cytokine implicated in inflammat

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
B-LymphocytesHumansDiabetes MellitusDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Interleukin-8Interleukin-10CytokinesFlow CytometryAdult

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research